Importance 37
Broad and potent neutralizing antibodies (bnAbs) with multiple epitope specificities evolve in 16 HIV-1 infected children. Herein we studied two antiretroviral naïve chronically HIV-1C in-17 fected monozygotic pediatric twins AIIMS_329 and AIIMS_330 with potent plasma bnAbs. 18 Elite plasma neutralizing activity was observed since initial sampling at 78 months in 19 AIIMS_330 and persisted throughout, while in AIIMS_329 it was seen at 90-months of age 20 after which potency decreased overtime. We evaluated potential viral characteristics associat-21 ed with the varied immune profile by generating single genome amplified pseudoviruses. The 22 AIIMS_329 viruses generated from 90-month time point sampling were neutralization sensi-23 tive to second generation bnAbs and contemporaneous autologous plasma antibodies, while 24 viruses from 112-months and 117-month timepoints were resistant to most bnAbs and autol-25 ogous contemporaneous plasma. AIIMS_329 viruses developed resistance to plasma nAbs 26 plausibly by N160-glycan loss, V1-and V4-loop lengthening. The viruses generated from 27 AIIMS_330 at 90-month and 117-month timepoint showed varied susceptibility to bnAbs and 28 autologous contemporaneous plasma antibodies while the viruses of 112-month timepoint, at 29 which plasma nAb specificities mapped to the V2-glycan, V3-glycan and CD4bs, were re-30 sistant to autologous contemporaneous plasma antibodies as well as most bnAbs. We ob-31 served evolution of a viral pool in AIIMS_330 donor, comprising of plasma antibody neutral-32 ization sensitive or resistant diverse autologous viruses that in turn may have contributed to 33 development and maintenance of elite neutralizing activity. The findings of this study provide 34 information towards understanding factors involved in generation and maintenance of potent 35 plasma nAbs. 36
Introduction 53
Disease progression in HIV-1 infected children is observed to develop in a biphasic manner. 54 More than 50% of the infected children, if not initiated on antiretroviral therapy (ART), pro-55 gress to AIDS within a couple of years of infection due to an immature immune system and 56
higher levels of viral replication (1, 2) . Infected children who survive beyond the initial years 57 mostly develop chronic disease (3) with slow progression. HIV-1 infected children have 58 been shown to mount potent plasma broadly neutralizing antibodies (bnAbs) earlier than 59 adults and more frequently with multiple bnAb specificities. than adults (4-6). The bnAb 60 BF520.1 was recently isolated from an infant one-year post-infection (p.i) (4,7) . The pres-61 ence of epitopes, targeted by the second generation bnAbs, on the functional native like HIV-62 1 envelope trimers identifies such envelopes as candidates for HIV-1 immunogen design. The 63 native-like HIV-1 gp140 trimeric envelope glycoprotein BG505.T332.SOSIP.664.C2 T332N 64 (8-10), generated from the circulating virus of a clade A infected infant, is the best immuno-65 gen documented so far. A recent study on 303 HIV-1 transmission pairs showed that among 66 majority of infecting viral strains, only few had the ability to induce bnAb responses (11). 67
Tracing the virological characteristics of such rare viral antigens capable of initiating and 68
shaping potent antibody responses to HIV-1 will provide key insights for future vaccine strat-69 egies capable of eliciting similar bnAb responses (11,12). Thus, pediatric HIV-1 infection, 70
with its unique characteristics of rapid and frequent induction of potent bnAbs with multiple 71
specificities, provides a unique model to understand the virological characteristics that can be 72 utilized for future HIV-1 vaccine candidates capable of inducing bnAbs. 73
Chronically infected children have been shown to have potent plasma bnAbs with diverse 74 epitope specificities (5, 6 ternal twins to evaluate for variation in the C2-C5 viral sequence or viremia showed that in 87 majority of the twin pairs, minimal sequence variation was seen in the early viruses indicat-88
ing that they were infected by the same or closely related quasispecies from the mother. Over 89 time, the viruses showed divergence. The similar viral levels observed in these twins further 90
suggested that inherent viral properties determine the pattern of viral expression with a mini-91 mal role of host genetics (20). 92
We evaluated AIIMS_329 and AIIMS_330 for a period of 60 months, with time matched 93 sampling since their baseline sampling in 2013, to decipher the viral characteristics responsi-94 ble for the induction and sustenance of potent plasma bnAbs. One of the twins, AIIMS_330, 95
showed elite neutralizing activity at first sampling that improved with time. The AIIMS_330 96 plasma showed polyclonal bnAb response with multiple bnAb specificities that increased in 97 potency in the follow up time points, and had multiple circulating viral variants with varied 98 susceptibility to contemporaneous autologous plasma antibodies and bnAbs. The plasma of 99 the second twin AIIMS_329, also developed elite neutralizing activity, although at a later 100 time point. In order to determine the virological traits associated with the diverse plasma 101 bnAb response, we generated envelope pseudoviral clones of the circulating viruses from the 102 twin plasma samples at different time points and tested their susceptibility to neutralization 103 by the contemporaneous and evolving plasma antibodies and to the known bnAbs to identify 104 the neutralizing determinants on these viruses of pediatric origin. AIIMS_329 showed the 105 presence of circulating viral variants that were resistant to autologous contemporaneous 106 plasma and bnAb neutralization. Taken together, our data shows the presence of multiple and 107 distinct circulating viral variants, with varied susceptibility to autologous plasma antibodies 108
and bnAbs in each of the two genetically identical HIV-1 infected twins, that impacted the 109 varied evolution of polyclonal bnAb response despite the similar genetic background in the 110 twins. 111
Results 112
Varied evolution of plasma antibodies in genetically identical twins against diverse 113 clades of HIV. 114
In this study, we evaluated a total of nine independent and time-matched plasma samples 115 from AIIMS_329 and AIIMS_330 pediatric HIV-1C infected twin donors, earlier established 116
as LTNPs (6). High resolution HLA typing revealed that AIIMS_329 and AIIMS_330 were 117 identical at HLA-A, B, DRB1 loci, and contained wild type CCR5 alleles (data not shown). 118
The detailed two field HLAs were HLA-A*02:11, *24:02; B*35:03*40:06; 119 DRB1*14:04*15:01. The baseline (First) sampling of the identical twins was done at the age 120 of 78-months, and they were then longitudinally followed up for a period of 60 months upto 121 the age of 138-months. The CD4+ T cell counts and viral loads of respective time-points are 122
given in Table 1 . 123
A longitudinal assessment of evolution of plasma antibodies of AIIMS_329 and AIIMS_330 124 was done over a period of 60 months utilizing a standardized panel of 12 HIV-1 envelope 125 pseudoviruses that represent strains circulating across the globe (21). The HIV-1 neutralizing 126 activity of plasma antibodies was assessed by performing neutralization assays using TZM-bl 127 based luciferase reporter assay. At the 78-month sample, the plasma antibodies of both the 128 twins showed potent neutralizing activity against most of the pseudoviruses in the panel (10 129 out of 12 for AIIMS_329 and 9 out of 12 for AIIMS_330) (Figure 1A and C) . The 130
AIIMS_330 plasma antibodies demonstrated increase in neutralization breadth (from 75% to 131 100% viruses neutralized) and potency (GMT titres from 204 to 929) over time, and reached 132 a maximum ID50 titre of 966 at 117-months, that persisted till the last sample time point 133 (Figure 1C-D) . Of particular note was the neutralization of majority of viruses at plasma di-134 lution of 300 or more. In case of AIIMS_329, the potency (GMT titres from 244 to 384) in-135 creased up to 90 months, followed by a reduction in neutralizing antibody potency (GMT ti-136 tres of 93), that stabilized at 112 months till the final sample time point (GMT titre 124). 137
( Figure 1A-B ). There was a reduction in AIIMS 329 plasma antibody ID50 titre against non-138 clade C viruses, whereas the titre against 25710_2_43 pseudovirus (Indian clade C), despite 139
showing a reduction, was maintained in the range of ID50 300-700. 140
To substantiate this observation and to evaluate for elite neutralizing activity, we further as-141 sessed plasma neutralizing activity using an extended multiclade 45 virus panel. With the ex-142 tended panel of viruses, viral neutralization was checked with plasma follow up time points 143 until 112 months, since both the twins showed ability of plasma antibodies to neutralize the 144 global panel of viruses beyond the age of 112 months. AIIMS_329 plasma showed elite neu-145
tralizing activity at 90-months after which the plasma potency decreased overtime, against 146
non-clade C viruses (Figure 2A-B) . As observed with the 25710 clade C pseudovirus in the 147 global panel, AIIMS_329 plasma maintained its neutralization activity against the tested 148 clade C viruses of Indian origin, unlike the reduction seen in the ability to neutralize non-149 clade C viruses ( Figure 2B ). AIIMS_330 plasma in its baseline sampling at 78-months 150 showed elite neutralizing activity against the 45-virus panel, i.e., with ability to neutralize 151 more than one pseudovirus at a dilution of 300 or more within a clade group and across at 152 least four clade groups (Figure 2C ). For AIIMS_330, unlike AIIMS_329, the elite neutraliz-153
ing activity consistently increased in potency overtime till the final time point sampling, with 154 the most noteworthy increase in titres observed at 112 months. As we had observed a plateau 155 in ID50 titres beyond this time point with the global panel of viruses, we did not perform fur-156 ther neutralization assays of samples after 112 months of follow up. 157 AIIMS_330 developed antibodies targeting V2-glycan, V3-glycan and CD4bs epitopes 158 with increase in potency of V2-glycan antibodies with time. 159
In order to identify the neutralizing specificities of AIIMS_329 and AIIMS_330 plasma anti-160 bodies that may have contributed to their potent neutralizing activity, we tested plasma neu-161 tralization of mutant pseudoviruses harbouring mutations at key residues of V2-glycan and 162
V3-glycan to assess glycan dependence (5,6), binding reactivity with RSC3 wild type probe 163 and its mutant RSC3Δ371I/P363N (22) for presence of CD4bs dependence and MPER pep-164 tides (MPER-B and -C) (23,24) for MPER dependence. 165
To test for V2 glycan dependence, we used N160A mutants of BG505 and 16055 pseudo-166 viruses. Dependence was assigned when neutralizing activity for both the mutant viruses 167 were at least 3-fold lesser than that of the corresponding wild type virus. Based on these crite-168 ria, V2 glycan directed neutralizing antibodies were found in AIIMS_330 plasma at all time 169 points including the baseline, while AIIMS_329 showed the emergence of V2 glycan directed 170 plasma neutralizing antibodies at 102-months, the timepoint at which AIIMS_329 plasma an-171 tibodies demonstrated elite neutralizing activity (Table 2) . In both twins, plasma V2 glycan 172 dependent neutralizing activity increased with time. As V2-glycan antibodies also target resi-173 dues other than N160 in the V1 and V2 loops, we next assessed the dependence on N156, 174 K169, and K171 residues using alanine mutants of 16055 virus, and both the twins did not 175
show any dependence on N156, K169, and K171, suggesting that plasma V2-glycan antibod-176 ies depended solely on N160 (Table 2) . Testing for the N332 dependence using the N332A 177 mutants of CAP256 and BG505 N332 viruses showed that V3 supersite glycan directed nAbs 178 evolved 117-months onwards in the plasma of both twins (Table 2) . 179
The presence of CD4bs directed antibodies was determined by performing ELISAs using 180 wild type RSC3 protein and its mutant RSC3Δ371I/P363N. The CD4bs directed bnAb 181 VRC01 was used as a positive control. The plasma of a healthy HIV-1 seronegative donor 182
and 447-52D mAb were used as negative controls. A reduction of three-fold or more in bind-183
ing to RSC3Δ371I/P363N compared to RSC3 was scored as positive for the presence of 184
CD4bs directed antibodies. AIIMS_330 plasma showed presence of CD4bs antibodies at 112-185 and 117-months, which at later timepoints waned and no CD4bs dependence was seen at 131 186 and 138 months (Table 3 ). AIIMS_329 did not show a significant difference in binding to 187 RSC3 and RSC3Δ371I/P363N at all timepoints tested, indicating the absence of CD4bs di-188 rected antibodies in the plasma. For presence of antibodies against MPER, ELISA binding 189 assay using MPER peptides was used. The MPER directed bnAb 2F5, was used as a positive 190 control and an HIV-1 seronegative healthy donor plasma was used as negative control. We 191 did not observe MPER directed plasma antibodies in any of the time points tested for both the 192 twin plasma samples (Data not shown). 193
Autologous resistant viruses of both the twins showed distinct mechanisms to escape 194
contemporaneous plasma antibodies as well as bnAbs. 195
As seen in plasma neutralization and mapping assays, the most striking differences observed 196 in both the twins were in the timeframe of 90-months to 117-months with a distinct reduction 197 in AIIMS_329 and increase in AIIMS_330 plasma neutralization potency, and dependence on 198 multiple epitopes. In order to determine the potential viral characteristics associated with the 199 varied immune profile in both the twins, we generated pseudoviruses by single genome am-200 plification (SGA) of the envelope gene from HIV-1 RNA, isolated from the plasma. Further, 201 all the amplicons generated by SGA were directly sequenced to assess the viral diversity. At 202 least 20 amplicons from each timepoint were sequenced to give a 90% confidence interval, to 203 cover most of the circulating strains. The sequences of the viral amplicons were checked for 204 their clade (REGA HIV Subtyping Tool), pairwise distance to reference sequence (Phylo-205
Place) and co-receptor usage (Web PSSM). All amplicons belonged to Clade C, had the 206 highest phylogenetic relatedness to the reference sequence C.IN.95.95IN21068.AF067155 207 with a median pairwise sequence distance of 0.093, and utilized CCR5 as the co-receptor. All 208 the AIIMS_329 viruses generated from the 90-month time point sampling were susceptible to 209 neutralization by the majority of the second generation bnAbs as well as contemporaneous 210 autologous plasma antibodies. The pseudoviruses generated from 112-months and 117-month 211 timepoints were resistant to most of the bnAbs and less susceptible to neutralization by the 212 autologous contemporaneous plasma (Table 4 ). The viruses generated from AIIMS_330 from 213 90 and 117-months, except for one pseudovirus from 117-mo timepoint showed varied sus-214 ceptibility to bnAbs and were susceptible to neutralization by autologous contemporaneous 215 plasma antibodies. The AIIMS_330 pseudoviruses of 112-month timepoint, at which plasma 216 neutralizing antibodies specificities mapped to the V2-glycan, V3-glycan and CD4bs, were 217 less susceptible to neutralization by most bnAbs and resistant to autologous contemporaneous 218 plasma antibodies as well as (Table 4) . 219
The sequences of SGA amplified envelope genes representing the circulating strains of both 220 the twins at 90 -months were used to construct a phylogeny tree in order to identify the most 221 recent common ancestor (MRCA) (Figure 3 ), which in turn was used as a reference sequence 222
to generate highlighter plots (HIV Database). The highlighter plots for AIIMS_329 showed 223 maximum divergence in V2C2, V3C3 and V4C4, with V4C4 envelope regions, with V4 loop 224 lengthening, and acquiring the most PNGS (Potential N-linked glycosylation sites) in 112-225
and 117-months timepoint samples ( Figure 4 ). In case of AIIMS_330, major divergence was 226 observed in V2C2 and V4C4 regions of envelope glycoprotein in 112 and 117 time point 227 samples ( Figure 5 ). As V1V2 loops have been shown to be involved in virus escape from 228 bnAbs, we aligned V1V2 loops of AIIMS_329 and AIIMS_330 to identify the key residues 229 involved in resistance to known bnAbs as well as the autologous plasma. In case of 230 AIIMS_329 virus, the key glycan residue N160 was mutated to Y, thereby leading to loss of 231 N160 glycan. As the plasma V2-glycan directed antibodies in AIIMS_329 were solely de-232 pendent on N160, the N160Y mutation may be one of the potential escape mechanisms em-233 ployed by AIIMS_329 viruses against contemporaneous plasma antibodies. In case of 234 AIIMS_330, the key residues at N156, N160, K171 were preserved in the viruses resistant to 235 autologous plasma antibodies, the resistant viruses however had longer V1 and V2 loops with 236 increased PNGS ( Figure 6 ). The viruses of AIIMS_329 probably developed resistance to au-237 tologous plasma antibodies by V1 and V4 loop lengthening (25,26) increased number of 238 PNGS and loss of critical epitopes like N160 (Table 6 and The plasma neutralizing activity of both twins was assessed over a period of 60 months, with 262 the first sampling at 78-months post-infection (p.i.), using a global standard panel of 12 HIV-263 1 envelope pseudoviruses (21). A consistent increase in potency, median ID50 neutralization 264 titre and GMT was observed for AIIMS_330 plasma, that peaked at 112-months post infec-265 tion (p.i), and then reached a plateau throughout the duration of the study. AIIMS_329, on the 266 other hand, showed highest GMT, median ID50 neutralization and potency at 90-months p.i, 267
which then declined at 112-months p.i, beyond which the titres stabilized. In both HIV-1 268 infected adults and children, a continuous increase in breadth and potency of plasma antibod-269
ies is well established (6,28,29), however a reduction in breadth and potency of the 270 AIIMS329 plasma neutralizing antibodies at 112-months p.i, while maintaining a stable 271
CD4 further confirmed that the AIIMS_329 plasma antibodies were progressively less effective in 277 cross neutralizing activity while retaining their ability to neutralize viruses of Indian origin. 278
The AIIMS_330 plasma showed elite neutralizing activity from 78-months p.i, which may 279
have developed due to the persistent antigenic stimulus by the high viremia seen in this twin 280
as compared to AIIMS_329. Long exposure to high viral load with declining CD4 + T cell 281 counts has been earlier shown to be associated with development of plasma breadth and po-282 tency over time (28). 283
The epitope specificities of plasma bnAbs for AIIMS_329 and AIIMS_330 were assessed by 284 performing neutralization assays using N160A V2-glycan mutants, N332A V3-glycan (mu-285 tants, CD4bs probe RSC3 and its mutant RSC3Δ371I/P363N, as well as MPER peptides 286
MPER-B and -C. AIIMS-330 plasma showed dependence on N160A glycan at 78-month p.i 287 (baseline sample) which increased in potency over time (From 4.1 to 8.9), whereas AIIMS-288 329 plasma showed N160A glycan dependence 102-months p.i, two years later than AIIMS-289 330. No reduction was observed with 16055 virus and its mutants N156K, K169A and 290 K171A, indicating that the V2-glycan dependence was mostly on the N160 epitope in V2 291
apex. Both the twins showed V3-glycan dependence at 112-months p.i. At 112-month, 292
AIIMS-330 plasma also developed CD4bs dependence whereas AIIMS-329 failed to generate 293
CD4bs dependence throughout the duration of the study. Neither twin generated MPER de-294
pendence. Both the twins developed primary neutralizing response against V2 glycans to 295 begin with, which is in accordance with several studies showing V2 glycan bnAbs to be most 296 common and potent (29,30). Many studies have shown that children mount broader and more 297 potent response against HIV-1 earlier than adults with one report showing the presence of 298 broad neutralizing activity in one infant one-year p.i (4,7). Polyclonal bnAb responses in 299
HIV-1 infection have been well reported in instances of both adult and pediatric infection 300 (31-33), with chronic infection and higher antigenic stimulation, often identified as factors 301 responsible for neutralization dependence on multiple specificities. Our observation of dual 302 epitope specificity in the AIIMS-329 plasma and antibodies against 3 distinct epitopes in 303
AIIMS-330 plasma that developed by 112-months of age is in consonance with the findings 304 of a recent study wherein children infected with HIV-1 for a duration of ten years on average 305 were found to have multiple HIV-1 nAb specificities (5). Based on the multiple epitope spec-306
ificities observed in AIIMS-330 plasma 112-months p.i, and the highest GMT titres and me-307 dian ID50 values obtained from the contemporaneous plasma mapping analysis using the 45-308 virus panel, we inferred that the spike observed in AIIMS-330 plasma BCN activity at the 309 fifth follow-up was probably due to the development of V3-glycan and CD4bs dependence at 310 the same timepoint. Despite the presence of plasma neutralization antibodies with multiple 311 epitope specificities, and having similar antigenic exposure, genetic and ethnic background, 312
both twins continued to have viremia and developed different plasma neutralization profile 313 and dependency with time. 314
Both the virus and antibody responses in the host are known to co-evolve, and a continuous 315 interplay between HIV-1 envelope specific antibody response and viral escape is one of the 316 key features of bnAb development (12,34-39). In order to trace the viral evolution in these 317
twins that occurred along with the increase in the plasma antibody neutralizing activity with 318 time, we assessed the circulating viral strains in both the twins around the timepoint (90-319 months to 117-months) when they developed multiple specificities to delineate the viral 320
properties that may be associated with the altered plasma neutralization potency. To negate 321 the cloning bias often associated with conventional bulk PCR amplification approach, func-322 tional pseudoviruses representing circulating HIV-1 strains were generated via single genome 323 amplification of envelope genes, from HIV-1 RNA isolated from plasma samples of the twins 324
and their susceptibility to neutralization by contemporaneous plasma as well as bnAbs was 325 evaluated. To further strengthen that the functional pseudoviruses generated represented the 326 currently circulating viral strains, we sequenced more than 20 SGA PCR amplicons from 327 each time point studied with a 90% confidence (40). In AIIMS_330 plasma, we observed 328 diverse circulating viral strains; viruses that showed neutralization susceptibility to autolo-329 gous plasma antibodies and bnAbs as well as resistant viruses, throughout the timeframe of 330 90-months to 117-months p.i. In AIIMS_329, the viruses generated at 90-month p.i were sus-331 ceptible to majority of the bnAbs as well as contemporaneous autologous plasma antibodies, 332
with the viruses generated from 112-months and 117-months p.i. resistant to bnAbs and con-333 temporaneous autologous plasma. We observed two distinct evolutionary pathways of viral 334 escape in response to increasing plasma potency and breadth in the twins. with an added advantage of matched timepoint assessments between two infected individuals 356 belonging to one transmission pair. Our findings are in corroboration with previously pub-357
lished reports suggesting that loop lengthening with increased glycan density contributes to 358 the development of viral resistance to V2-apex bnAbs. In addition, we observed potential vi-359 ral evolution in AIIMS_330 donor, harbouring a viral pool constituting autologous plasma 360
resistant and sensitive viruses that may have contributed to the development and maintenance 361 of elite neutralizing activity. The data emerging from the study of evolving viruses and plas-362 ma antibodies in this pair of HIV-1C chronically infected identical twins is supportive of en-363 velope-based lineage vaccine approaches that are currently being evaluated. This strategy is 364 based on use of a mixture of immunogens with different antibody imprinting ability rather 365 than one immunogen with susceptibility to all bnAbs, that could provide better antigenic ex-366 posure, higher antigenic variability for enhanced somatic hypermutation, and may lead to in-367 duction of antibodies with increased potency and breadth and our data is supportive of this 368 strategy. 369
Materials and methods 370
Study Population 371 AIIMS_329 and AIIMS_330 were recruited from Outdoor Patient Department of Department 372 of Pediatrics, AIIMS for this study at the age of nine years and were followed for a total peri-373 od of 60 months. Blood was drawn in 5-ml EDTA vials, plasma was aliquoted for plasma 374 neutralization assays and viral RNA isolation, and viral loads. The study was approved by 375 institute ethics committee of All India Institute of Medical Sciences (IEC/NP-295/2011 & 376 RP-15/2011). 377
Plasmids, viruses, monoclonal antibodies, peptides, and cells 378
Plasmids encoding HIV-1 env genes representing different clades, monoclonal antibodies and 379 TZM-bl cells were procured from NIH AIDS Reagent Program. Plasmid encoding RSC3 380 wild type probe and its mutant RSC3Δ371I/P363N were kindly provided by John Mascola, 381
National Institute of Allergy and Infectious Diseases, USA. Plasmids for CAP256 and its 382
N332A mutant was kindly provided by Lynn Morris, National Institute of Communicable 383
Diseases, SA. MPER-B and -C peptides were commercially synthesized from Sigma Geno-384 sys, USA (23,24). HEK293T cells were purchased from American Type Culture Collection 385 (ATCC). 386
Cloning of autologous HIV-1 envelope genes and production of replication incompetent 387 pseudoviruses 388
Autologous replication incompetent envelope pseudoviruses were generated from 389 AIIMS_329 and AIIMS_330 as described previously (44). Briefly, viral RNA was isolated 390 from 140 µl of plasma using QIAamp Viral RNA Mini Kit, reverse transcribed, using gene 391 specific primer OFM19 and Superscript III reverse transcriptase, into cDNA which was used 392 in two-round nested PCR for amplification of envelope gene using High Fidelity Phusion 393 DNA Polymerase (New England Biolabs). The envelope amplicons were purified, and ligated 394 into pcDNA3.1D/V5-His-TOPO vector (Invitrogen). Pseudoviruses were prepared by co-395 transfecting 1.25 µg of HIV-1 envelope containing plasmid with 2.5 µg of an envelope defi-396 cient HIV-1 backbone (PSG3Δenv) vector at a molar ratio of 1:2 using PEI-MAX as transfec-397 tion reagent in HEK293T cells seeded in a 6-well culture plates. Culture supernatants con-398 taining pseudoviruses were harvested 48 hours post-transfection, filtered through 0.4µ filter, 399
aliquoted and stored at -80 o C until further use. TCID50 was determined by infecting TZM-bl 400 cells with serially diluted pseudoviruses in presence of DEAE-Dextran, and lysing the cells 401 48 hours post-infection. Infectivity titres were determined by measuring luminescence activi-402 ty in presence of Bright Glow reagent (Promega). 403
HIV-1 envelope sequences and phylogenetic analysis 404
HIV-1 envelope genes were PCR amplified from plasma viral RNA by single genome ampli-405 fication (40) and directly sequenced commercially. Individual sequence fragments of SGA 406 amplified amplicons were assembled using Sequencher 5.4 (Gene Code Corporation). Nucle-407 otide sequences were aligned in MEGA X (45) and phylogeny trees for identifying the most 408 recent common ancestor were constructed by the neighbour-joining method with 100 boot-409 strap replicates (44). 410
Neutralization assay 411
Neutralization assays were carried out using TZM-bl cells, a genetically engineered HeLa 412 cell line that constitutively expresses CD4, CCR5 and CXCR4, and contains luciferase and β-413 galactosidase gene under HIV-1 tat promoter, as described before (46). Briefly, envelope 414 pseudoviruses were incubated in presence of serially diluted bnAbs, or heat inactivated plas-415 mas for one hour. After incubation, freshly Trypsinized TZM-bl cells were added, with 25 416 µg/ml DEAE-Dextran. The plates were incubated for 48 h, cells were lysed in presence of 417
Bright Glow reagent, and luminescence was measured. Using the luminescence of serially 418 diluted bnAbs or plasma, a non-linear regression curve was generated and titres were calcu-419 lated as the bnAb concentration, or reciprocal dilution of serum that showed 50% reduction in 420 luminescence compared to untreated virus control. For V2-and V3-glycan dependence, 421 pseudoviruses with key mutation in V2-and V3-glycan were used with their wild type coun-422 terparts, and were incubated with plasma for one hour at 37 o C followed by addition of TZM-423 bl cells, and readout 48-hour post infection. 424
Binding ELISAs 425
MPER, RSC3 and RSC3Δ371I/P363N ELISAs were performed as described previously (16 Whitney U test was used to compare the ID50 titres of clade C vs non-clade C viruses. 626 AIIMS_330 (B) functional pseudoviruses, and distinct mechanism employed by them to es-642 cape autologous plasma neutralization. V1 and V2 loops are shown by the horizontal bar and 643 N160, the site for V2-glycan, is labelled with the vertical bar. 644 Plasma was serially diluted and tested for binding to RSC3 protein and its mutant 655 RSC3Δ371I/P363N by ELISA. Given are the OD values at 450 nm at plasma dilution of 656 1:100. VRC01, a CD4bs bnAb isolated using RSC3 probe, was used as positive control. 657 Table 4 -Neutralization susceptibilities of envelope pseudoviruses prepared from the plas-658 mas of both the twins to broadly neutralizing antibodies recognizing major epitopes of viral 659 envelope and contemporaneous autologous plasma. The IC50 of bnAbs and ID50 of plasmas 660
were determined in TZM-bl based neutralization assay by titrating the pseudoviruses with 661 serially diluted bnAbs and plasma. 662 
